The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12618000879268
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
24/04/2018
Date registered
Help: Date registered
25/05/2018
Date last updated
Help: Date last updated
14/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
17/02/2020
Date results provided
Help: Date results provided
14/08/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Targeted Oxygenation in the Respiratory care of Premature Infants at Delivery: Effects on Outcome (TORPIDO 30/60)
Scientific title
Lower or higher initial oxygen concentration with Targeted Oxygen saturation in Respiratory care of premature Infants at Delivery: effects on Outcome (TORPIDO 30/60)
Additional trial identifiers [1] 294612 0
CTC 0225
Universal Trial Number (UTN)
Trial acronym
Torpido 30/60
Related trial records

Health condition
Health condition(s) studied:
Premature infants requiring resuscitation at birth 307445 0
Condition category
Condition code
Reproductive Health and Childbirth 306530 306530 0 0
Complications of newborn

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
At delivery, a CPAP mask will be applied by the caregiver (e.g. midwife, neonatal clinician, obstetrician, anaesthetist), and initial FiO2 level will be set to 0.6. Using a pulse oximeter, FiO2 will be adjusted as required to achieve target SpO2 (80-85% at 5 min and 85-95% at 10 min and thereafter), until admission to the NICU.
Intervention code [1] 300919 0
Treatment: Drugs
Intervention code [2] 301076 0
Treatment: Devices
Description of the comparator or control
At delivery, a CPAP mask will be applied by the caregiver (e.g. midwife, neonatal clinician, obstetrician, anaesthetist), and initial FiO2 level will be set to 0.3. Using a pulse oximeter, FiO2 will be adjusted as required to achieve target SpO2 (80-85% at 5 min and 85-95% at 10 min and thereafter).
Control group
Dose comparison

Outcomes
Primary outcome [1] 305538 0
The composite primary outcome comprises survival free from major brain injury (assessed by routine ultrasound or other imaging and/or clinical assessment). Brain injury is defined as periventricular haemorrhage (on either side of the head) seen on ultrasound with grade 1-4, or the presence by ultrasound after 14 days of any of the following: echodense intraparenchymal lesions, periventricular leukomalacia (PVL) or porencephalic cysts
Timepoint [1] 305538 0
To 36 weeks gestation
Secondary outcome [1] 345663 0
All-cause mortality (from hospital records)
Timepoint [1] 345663 0
Death occurring on any day between birth and discharge home.
Secondary outcome [2] 345664 0
Major brain injury from any imaging performed before discharge home. Brain injury is defined as periventricular haemorrhage (on either side of the head) seen on ultrasound with grade 1-4, or the presence by ultrasound after 14 days of any of the following: echodense intraparenchymal lesions, periventricular leukomalacia (PVL) or porencephalic cysts
Timepoint [2] 345664 0
From any imaging performed before discharge home.
Secondary outcome [3] 346309 0
Tertiary Outcome (Hypothesis Generating) - Oxygen saturation (SpO2) will be monitored using a pulse oximeter until admission to NICU
Timepoint [3] 346309 0
From birth until admission to NICU
Secondary outcome [4] 346310 0
Tertiary Outcome (Hypothesis Generating) - Measured (by pulse oximeter) in 1 minute increments for the first 10 minutes of life and every 5 minutes thereafter until admission to NICU, the time it takes to reach SpO2 greater or equal to 80%
Timepoint [4] 346310 0
From birth until SpO2 reaches 80%
Secondary outcome [5] 346311 0
Tertiary Outcome (Hypothesis Generating) - Heart rate at each minute for the first 10 minutes after birth and then every 5 minutes until admission to NICU will be taken from hospital records.
Timepoint [5] 346311 0
From birth until admission to NICU
Secondary outcome [6] 346312 0
Tertiary Outcome (Hypothesis Generating) - Endotracheal Intubation in delivery suite required due to depressed respiratory effort (taken from hospital records).
Timepoint [6] 346312 0
From birth until admission to NICU
Secondary outcome [7] 346313 0
Tertiary Outcome (Hypothesis Generating) - Apgar scores (a summary of the health of the newbown) at 1 and 5 minutes
Timepoint [7] 346313 0
At 1 and 5 minutes of life
Secondary outcome [8] 346314 0
Tertiary Outcome (Hypothesis Generating) - Number of infants with severe periventricular haemorrhage from any imaging performed before discharge home.
Timepoint [8] 346314 0
From birth until discharge home
Secondary outcome [9] 346315 0
Tertiary Outcome (Hypothesis Generating) - Number of infants with Broncho-pulmonary dysplasia (BPD) defined as requirement for supplemental oxygen or respiratory support survival to 36 weeks, collected from hospital records.
Timepoint [9] 346315 0
36 weeks gestation.
Secondary outcome [10] 346316 0
Tertiary Outcome (Hypothesis Generating) - Number of infants with severe retinopathy of prematurity (ROP) as assessed by an ophthalmologist in the neonatal unit.
Timepoint [10] 346316 0
From birth until discharge home
Secondary outcome [11] 346317 0
Tertiary Outcome (Hypothesis Generating) - Number of infants with necrotising enterocolitis (NEC) confirmed with radiolographs, associated with surgery or death.
Timepoint [11] 346317 0
From birth until discharge home
Secondary outcome [12] 346318 0
Tertiary Outcome (Hypothesis Generating) - Number of infants with late onset sepsis will be collected from hospital records.
Timepoint [12] 346318 0
From 48 hours of life until discharge home
Secondary outcome [13] 346319 0
Tertiary Outcome (Hypothesis Generating) - Number of infants with Patent ductus arteriosus (PDA) will be collected from hospital records.
Timepoint [13] 346319 0
From birth until discharge home
Secondary outcome [14] 346320 0
Tertiary Outcome (Hypothesis Generating) - Duration of hospital stay defined as the number of days from admission to final discharge home (taken from hospital records).
Timepoint [14] 346320 0
From birth until discharge home
Secondary outcome [15] 346321 0
Tertiary Outcome (Hypothesis Generating) - Survival without major disability at 2-3 years corrected for gestation. Disability will be assessed by one or more of the following assessments: a) The Bayley Scales of Infant Development (BSID); b) The Ages and Stages Questionnaire (ASQ); c) Short Health Status Questionnaire (SHQ) The ASQ and SHQ will be collected for all participants, and the BSID will be collected where routinely done.
Timepoint [15] 346321 0
at 24-36 months corrected age.

Eligibility
Key inclusion criteria
Premature infants born from 23/0 to 28/6 weeks gestation
Minimum age
23 Weeks
Maximum age
29 Weeks
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Any known major cardiopulmonary abnormalities that could affect oxygenation or congenital malformations that could affect neuro-developmental outcome or survival

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation by computer
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Treatment allocation will be stratified by study site, gestation and multiplicity.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Efficacy
Statistical methods / analysis
A trial of 735 infants per arm (1470 total sample size) provides 85% power, with a 2 sided 5% significance level, to detect an absolute risk difference of 32% versus 24% (i.e. 25% a relative risk reduction) in the primary endpoint (brain injury free survival to 36 weeks) whilst allowing for 10% non-adherence to assigned protocol treatment. Multiple babies from the same birth will be randomised together and an intra-cluster correlation of 0.3 and an average cluster size of 1.15 is assumed.
The sample size is based on current and conservative assumptions about event rates and compliance. These parameters will be reviewed at the interim analysis and sample size will be adjusted if required.

A detailed statistical analysis plan will be prepared. All randomised subjects will be eligible for inclusion in the full analysis set in accordance with the intention-to-treat analysis principle. Comparisons between randomised groups that take stratification factors into account will be undertaken using tests for categorical variables and linear models for continuous variables. Sensitivity of results to adjustment for other covariates and possible clustering between multiples will be explored. Subgroup analyses will be specified in the statistical analysis plan.

Recruitment
Recruitment status
Active, not recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,NT,QLD,SA,VIC
Recruitment hospital [1] 15899 0
The Canberra Hospital - Garran
Recruitment hospital [2] 15900 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [3] 15901 0
Royal Hospital for Women - Randwick
Recruitment hospital [4] 15902 0
Gold Coast Hospital - Southport
Recruitment hospital [5] 15903 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [6] 20539 0
Royal Darwin Hospital - Tiwi
Recruitment hospital [7] 20540 0
John Hunter Hospital - New Lambton
Recruitment hospital [8] 20541 0
Westmead Hospital - Westmead
Recruitment postcode(s) [1] 29356 0
2605 - Garran
Recruitment postcode(s) [2] 29357 0
2050 - Camperdown
Recruitment postcode(s) [3] 29358 0
2031 - Randwick
Recruitment postcode(s) [4] 29359 0
4215 - Southport
Recruitment postcode(s) [5] 29360 0
5042 - Bedford Park
Recruitment postcode(s) [6] 35321 0
0810 - Tiwi
Recruitment postcode(s) [7] 35322 0
2305 - New Lambton
Recruitment postcode(s) [8] 35323 0
2145 - Westmead
Recruitment outside Australia
Country [1] 10290 0
India
State/province [1] 10290 0
Bangalore
Country [2] 10291 0
Malaysia
State/province [2] 10291 0
Kuala Lumpur
Country [3] 10292 0
Singapore
State/province [3] 10292 0
Bukit Timah
Country [4] 22359 0
United States of America
State/province [4] 22359 0
New Jersey
Country [5] 24132 0
Spain
State/province [5] 24132 0
Madrid

Funding & Sponsors
Funding source category [1] 299229 0
Government body
Name [1] 299229 0
National Health and Medical Research Council
Country [1] 299229 0
Australia
Funding source category [2] 322750 0
Charities/Societies/Foundations
Name [2] 322750 0
Thrasher Research Fund
Country [2] 322750 0
United States of America
Primary sponsor type
University
Name
University of Sydney
Address
The University of Sydney
NSW 2006
Country
Australia
Secondary sponsor category [1] 298501 0
None
Name [1] 298501 0
Address [1] 298501 0
Country [1] 298501 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 300154 0
Hunter New England Local Health Distritct
Ethics committee address [1] 300154 0
Ethics committee country [1] 300154 0
Australia
Date submitted for ethics approval [1] 300154 0
28/11/2017
Approval date [1] 300154 0
12/06/2018
Ethics approval number [1] 300154 0
17/12/13/3.03
Ethics committee name [2] 305391 0
HREC of the Northern Territory Department of Health and Menzies School of Health Research
Ethics committee address [2] 305391 0
Ethics committee country [2] 305391 0
Australia
Date submitted for ethics approval [2] 305391 0
23/04/2019
Approval date [2] 305391 0
02/01/2020
Ethics approval number [2] 305391 0
2019-3400

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 51254 0
Dr Ju-Lee Oei
Address 51254 0
Neonatal Intensive Care Unit Royal Hospital for Women Randwick, NSW 2031
Country 51254 0
Australia
Phone 51254 0
+61 2 9382 6152
Fax 51254 0
Email 51254 0
Contact person for public queries
Name 51255 0
Trial Coordinator
Address 51255 0
c/o TORPIDO30/60 Coordinator Locked Bag 77 Camperdown NSW 1450
Country 51255 0
Australia
Phone 51255 0
+61 2 9562 5000
Fax 51255 0
Email 51255 0
Contact person for scientific queries
Name 51256 0
Ju-Lee Oei
Address 51256 0
Neonatal Intensive Care Unit Royal Hospital for Women Randwick, NSW 2031
Country 51256 0
Australia
Phone 51256 0
+61 2 9382 6152
Fax 51256 0
Email 51256 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• De-identified individual participant data:
• Published results
What types of analyses could be done with individual participant data?
• Individual patient data analysis and pooled analysis

When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
No end date
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Analytic code    This will be provided when data is shared.
Informed consent form    This will be provided when data is shared.


Results publications and other study-related documents

Documents added manually

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseTargeted Oxygen for Initial Resuscitation of Preterm Infants: The TORPIDO 30/60 Randomized Clinical Trial.2026https://dx.doi.org/10.1001/jama.2025.23327
N.B. These documents automatically identified may not have been verified by the study sponsor.